Nexstim to present at 3rd Neurotech Investing & Partnering Summit in Geneva

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces today that Chief Executive Officer, Janne Huhtala, will be presenting at the Neurotech Investing & Partnering conference in Geneva at 11:30 CEST on Wednesday 9 September 2015.

The conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organisation and the industry. For information about the conference, please visit www.neurotechconfeurope.com. The Company’s presentation will be made available at www.nexstim.com following the conference.

Further information

Nexstim
Janne Huhtala, Chief Executive Officer
+358 (0)40 8615046

UB Capital Oy (Certified Adviser)
+358 (0)9 2538 0225

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Laura Thornton
+44 (0)20 3709 5700
nexstimconsilium-commscom

About Nexstim Plc

Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.